New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
08:47 EDTBAC, GS, JCP, AMZN, JOSB, MON, BCS, GOOG, UTX, PG, MW, BRK.A, ARO, HMC, GE, TGT, JPMOn the Fly: Periodicals Wrap
WSJ: JPMorgan's (JPM) Dimon: 'Silicon Valley wants to eat our lunch'...Judge fast-tracks Men's Wearhouse (MW) suit against Jos. A. Bank (JOSB)...Target (TGT) retaliates against P&G (PG) after Amazon deal (AMZN)...GE (GE), United Technologies (UTX) could be helped by Pentagon plan for engines...REUTERS: J.C. Penney (JCP) fails to make e-commerce gains...House committee demands Target (TGT) data breach documents...BLOOMBERG: Honda (HMC) to stop producing Insight hybrid...Google (GOOG) Glass faces possible driving ban from some states...Numerous Wall Street firms (JPM, GS) agree to stop analyst previews...Aeropostale (ARO) working with Barclays (BCS) to explore options...OTHER NEWS: Bank of America (BAC) capital levels helped by Berkshire (BRK.A) modification, FT reports...Monsanto (MON) at epicenter of intensifying food debate, FT reports.
News For A;MON From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 20, 2015
09:41 EDTMONSyngenta says Monsanto statement contains nothing new, Bloomberg reports
Subscribe for More Information
07:33 EDTMONMonsanto 'confident in ability' to address regulatory concerns in Syngenta deal
Subscribe for More Information
07:33 EDTMONMonsanto says on track in five-year plan to at least double ongoing EPS by 2019
Subscribe for More Information
07:31 EDTMONMonsanto says on track in five-year plan to at least double ongoing EPS by 2019
07:30 EDTMONMonsanto, Scotts Miracle-Gro expand long-standing agreement
Monsanto Company (MON) and The Scotts Miracle-Gro Company (SMG) announced the two companies have extended their nearly two-decade long partnership in the lawn and garden consumer market. Since 1999, Scotts Miracle-Gro, through one of its subsidiaries, has served as Monsanto's exclusive agent for the marketing and distribution of Roundup® non-selective herbicides in the consumer lawn and garden market within the United States and select international markets. Today’s agreement will unlock additional value in the Roundup brand in the lawn and garden segment by providing Scotts with an extended license to use the Roundup brand in new lawn and garden product categories and broaden their marketing rights into new geographies. As part of the extension, Monsanto also renewed and expanded the terms of its marketing agreement with Scotts and provided preferred access to Monsanto’s R&D pipeline for lawn and garden. Under the agreement, Scotts will pay Monsanto a one-time upfront payment of $300M in exchange for a Roundup® brand license, extended agency agreement and technology agreement.
07:07 EDTMONBMO Capital to hold a conference
10th Annual Farm to Market Conference is being held in New York on May 20-21 with webcasted company presentations to begin on May 20 at 8 am; not all company presentations may be webcasted. Webcast Link
07:06 EDTMONScotts Miracle-Gro announces agreement with Monsanto to extend Roundup brand
Scotts Miracle-Gro (SMG) announced an agreement with Monsanto (MON) that offers opportunities to extend the Roundup brand into new lawn and garden categories and geographies. The two companies also have reached a technology sharing agreement and have made amendments to the existing Roundup Agency Agreement that provide greater long-term security for ScottsMiracle-Gro. Key highlights to the agreements provide ScottsMiracle-Gro with enhanced security, as termination of the agreement no longer includes specific performance criteria. In the event Monsanto terminates the agreement, in certain circumstances, the company would receive a termination fee of no less than $200M and would retain its agency rights for at least 5 years. ScottsMiracle-Gro has agreed to pay Monsanto $300M in connection with these and other amendments to the current Agency Agreement and the brand extension and joint technology agreements. Financing will be accommodated under the company's existing credit facility. Because the ability to introduce new products and enter new geographies could take several years, the amended agreement modifies the existing commission structure. The result of the new structure is expected to offset financing costs and the expenses required for the development of new Roundup products and services.
May 19, 2015
07:15 EDTMONGoldman Sachs to hold a conference
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
May 17, 2015
14:32 EDTMONSyngenta shares show promise even without Monsanto deal, Barron's says
Shares of Syngenta (SYT) could be "worth a bet" even if Monsanto's (MON) takeover efforts flounder, Barron's contends in its 'International Trader - Europe' column. Barron's notes that the company's cost reduction measures could yield $265M in savings this year, a figure which may jump to $1B by 2018. Reference Link
May 15, 2015
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
07:26 EDTMONBayer expecting crops and seeds industry consolidation, Reuters reports
Subscribe for More Information
May 14, 2015
15:18 EDTMONMonsanto seeks buyer for Syngenta seeds ahead of takeover offer, Reuters says
Subscribe for More Information
May 13, 2015
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information
May 11, 2015
05:35 EDTMONSyngenta upgraded to Buy from Neutral at UBS
UBS upgraded Syngenta (STY) to Buy saying Monsanto (MON) is likely to raise its takeover bid for the company. The firm views antirust issues as manageable and believes Monsanto could offer as much as CHF535 per share for Syngenta.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use